Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

Advances in Anatomic Pathology

Volumn 16, Issue 5, 2009, Pages 267-282

  Vang, Russell ^a,b   Shih, Ie Ming ^a   Kurman, Robert J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Grading; High grade; Low grade; Ovary; Serous carcinoma

Indexed keywords

B RAF KINASE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P16; PROTEIN P53;

BEHAVIOR; CANCER GROWTH; CANCER INVASION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EVOLUTION; FIBROMA; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UTERINE TUBE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 69349088990     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181b4fffa     Document Type: Review

References (87)

1. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7-15.
2. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998;82:893-901. (Pubitemid 28104169)
3. Ayhan A, Kurman RJ, Vang R, et al. Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol. 2009;33:1220-1224
4. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319-1330.
5. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol. 2007;31:1007-1012. (Pubitemid 47012296)
6. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361-368.
7. Hsu CY, Bristow R, Cha MS, et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 2004;10:6432-6436. (Pubitemid 39346537)
8. Hsu CY, Kurman RJ, Vang R, et al. Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Hum Pathol. 2005;36:1049-1054. (Pubitemid 41443255)
9. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009;69:4036-4042.
10. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496-504. (Pubitemid 38436523)
11. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31:1168-1174. (Pubitemid 47207118)
12. Pohl G, Ho CL, Kurman RJ, et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 2005;65:1994-2000. (Pubitemid 40478629)
13. Salani R, Kurman RJ, Giuntoli R, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18:487-491. (Pubitemid 351668307)
14. Santillan A, Kim YW, Zahurak ML, et al. Differences of chemoresistance assay between invasive micropapillary/lowgrade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer. 2007;17:601-606. (Pubitemid 46743993)
15. Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108:510-514.
16. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518. (Pubitemid 38529752)
17. Shih I, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA. 2005;102:14004-14009. (Pubitemid 41377693)
18. Shvartsman HS, Sun CC, Bodurka DC, et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007;105:625-629.
19. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223-1228. (Pubitemid 34411626)
20. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486. (Pubitemid 36432423)
21. Singer G, Shih I, Truskinovsky A, et al. Mutational analysis of Kras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol. 2003;22:37-41. (Pubitemid 36014274)
22. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224. (Pubitemid 40170640)
23. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol. 2003;27:725-736.
24. Vang R, Shih I, Salani R, et al. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol. 2008;32:1667-1674.
25. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. Am J Surg Pathol. 2006;30:1209-1221. (Pubitemid 44454698)
26. Seidman JD, Soslow RA, Vang R, et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004;35:918-933. (Pubitemid 39037176)
27. Bell DA, Longacre TA, Prat J, et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol. 2004;35:934-948. (Pubitemid 39037177)
28. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005;29:707-723.
29. Alvarez AA, Moore WF, Robboy SJ, et al. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Gynecol Oncol. 2001;80:201-206.
30. Haas CJ, Diebold J, Hirschmann A, et al. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Virchows Arch. 1999;434:117-120.
31. Mayr D, Hirschmann A, Lohrs U, et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 2006;103:883-887. (Pubitemid 44821309)
32. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004;202:336-340.
33. Cho K, Shih I. Ovarian cancer. Annu Rev Pathol Mech Dis. 2009;4:287-313.
34. Ho CL, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915-6918. (Pubitemid 39330999)
35. Staebler A, Heselmeyer-Haddad K, Bell K, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol. 2002;33:47-59. (Pubitemid 34112952)
36. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65:10602-10612. (Pubitemid 41743756)
37. Nakayama K, Nakayama N, Kurman RJ, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006;5:779-785. (Pubitemid 44775134)
38. Nakayama N, Nakayama K, Yeasmin S, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008;99:2020-2028.
39. Davidson B, Zhang Z, Kleinberg L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006;12:5944-5950. (Pubitemid 44703753)
40. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14-25. (Pubitemid 39249487)
41. Pothuri B, Leitao M, Barakat R, et al. Genetic analysis of ovarian carcinoma histogenesis (Abstract). Gynecol Oncol. 2001;80:277.
42. Werness BA, Parvatiyar P, Ramus SJ, et al. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst. 2000;92:1088-1091. (Pubitemid 30616483)
43. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807-2816. (Pubitemid 41798292)
44. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
45. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. 2002;94:61-67. (Pubitemid 34082844)
46. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002;94:1396-1406. (Pubitemid 35154144)
47. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(suppl 2):S19-S32. (Pubitemid 40188615)
48. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer. 1994;73:1859-1864.
49. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165.
50. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9. (Pubitemid 351627965)
51. Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008;53:127-138. (Pubitemid 352032762)
52. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169. (Pubitemid 46175016)
53. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236. (Pubitemid 43740193)
54. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35. (Pubitemid 46092026)
55. Vang R, Wheeler JE. Diseases of the fallopian tube and paratubal region. In: Kurman R, Ronnett B, Ellenson L, eds. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York: Springer. In press.
56. Silva EG, Tornos CS, Malpica A, et al. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma. Mod Pathol. 1997;10:663-667. (Pubitemid 27321756)
57. Parker RL, Clement PB, Chercover DJ, et al. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol. 2004;23:265-272.
58. Seidman JD, Horkayne-Szakaly I, Cosin JA, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol. 2006;103:703-708. (Pubitemid 44602191)
59. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239-1251.
60. Yemelyanova A, Mao TL, Nakayama N, et al. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol. 2008;32:1800-1806.
61. Che M, Tornos C, Deavers MT, et al. Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells. Int J Gynecol Pathol. 2001;20:323-328. (Pubitemid 32937445)
62. Ishioka S, Sagae S, Terasawa K, et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol. 2003;89:447-452. (Pubitemid 36687791)
63. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 1993;50:347-351.
64. Hu CY, Taymor ML, Hertig AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol. 1950;59:58-67.
65. Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am. 1978;58:121-129.
66. Ayhan A, Taskiran C, Yigit-Celik N, et al. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer? Int J Gynecol Cancer. 2006;16:484-489.
67. Baekelandt M, Jorunn NA, Kristensen GB, et al. Carcinoma of the fallopian tube. Cancer. 2000;89:2076-2084.
68. Barda G, Menczer J, Chetrit A, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population- based study. Am J Obstet Gynecol. 2004;190:1039-1045. (Pubitemid 38561521)
69. Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol. 1996;60:393-396. (Pubitemid 26077623)
70. Bloss JD, Brady MF, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol. 2003;89:148-154.
71. Dubernard G, Morice P, Rey A, et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol. 2004;30:976-981. (Pubitemid 39462529)
72. Eltabbakh GH. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J Surg Oncol. 2000;73:148-152.
73. Jaaback KS, Ludeman L, Clayton NL, et al. Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int J Gynecol Cancer. 2006;16(suppl 1):123-128.
74. Khalifeh I, Munkarah AR, Lonardo F, et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol. 2004;23:162-169. (Pubitemid 38391776)
75. Moore KN, Moxley KM, Fader AN, et al. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:398-403.
76. O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29:1034-1041. (Pubitemid 41045547)
77. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100. (Pubitemid 44106724)
78. Yemelyanova A, Ji H, Shih I, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. In press.
79. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol. 2005;24:363-368. (Pubitemid 41368290)
80. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology. 2007;50:773-779.
81. Vang R, Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:653-663. (Pubitemid 46684203)
82. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs. GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103-113. (Pubitemid 46797025)
83. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
84. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29:1482-1489. (Pubitemid 41513298)
85. Lotan TL, Ye H, Melamed J, et al. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. In Press.
86. Nakayama K, Nakayama N, Davidson B, et al. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA. 2006;103:18739-18744. (Pubitemid 44913480)
87. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep. 2008;10:519-523.